1. Home
  2. Stocks
  3. Blissgvs Share Price
  • Chart
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs

    • Bliss GVS Pharma Share Price

    Small Cap
    ₹131.38
    -2.77 (-2.06%)
    18 September, 2024 02:42 BSE: 506197 NSE: BLISSGVS ISIN: INE416D01022

    Start SIP in Bliss GVS Pharma

    Start SIP

    Bliss GVS Pharma Performance

    Day Range

    • Low 131
    • High 135
    ₹ 131

    52 Week Range

    • Low 77
    • High 150
    ₹ 131
    • Open Price134
    • Previous Close134
    • Volume474010

    Bliss GVS Pharma Chart

    • Over 1 Month + 18.28%
    • Over 3 Month + 24.12%
    • Over 6 Month + 19.27%
    • Over 1 Year + 37.43%

    Bliss GVS Pharma Key Statistics

    P/E Ratio 17
    PEG Ratio 0.5
    Market Cap Cr
    Price to Book Ratio 1.4
    EPS 7.2
    Dividend 0.4
    Relative Strength Index 58.89
    Money Flow Index 66
    MACD Signal 3.44
    Average True Range 6.06

    Bliss Gvs Pharma Investment Rating

    • Master Rating:

    • Bliss Gvs Pharma has an operating revenue of Rs. 794.37 Cr. on a trailing 12-month basis. An annual revenue growth of 4% is not great, Pre-tax margin of 15% is great, ROE of 7% is fair but needs improvement. The company has a reasonable debt to equity of 4%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 11% and 13% from 50DMA and 200DMA. It is currently FORMING a base in its weekly chart and is trading around 5% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 29 which is a POOR score indicating inconsistency in earnings, a RS Rating of 54 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 59 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Bliss GVS Pharma Financials
    IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Oper Rev Qtr Cr 149164161171109143
    Operating Expenses Qtr Cr 12213913312998133
    Operating Profit Qtr Cr 272529421111
    Depreciation Qtr Cr 666654
    Interest Qtr Cr 122115
    Tax Qtr Cr 7-481232
    Net Profit Qtr Cr 19-11213476
    IndicatorMar 2024Mar 2023
    Total Revenue Annual Cr 639649
    Operating Expenses Annual Cr 498508
    Operating Profit Annual in Cr 10790
    Depreciation Cr 2415
    Interest Annual Cr 610
    Tax Annual Cr 2030
    Net Profit Annual Cr 5185
    IndicatorMar 2024Mar 2023
    Cash from Operating Activity Annual Cr 12644
    Cash from Investing Activity Annual Cr -110-13
    Cash from Financing Annual Activity Cr -21-26
    Net Cash Flow Annual Cr -45
    IndicatorMar 2024Mar 2023
    Total ShareHolders Funds Annual Cr 988937
    Fixed Assets Annual Cr 338328
    Total Non Current Assets Annual Cr 380410
    Total Current Assets Annual Cr 773730
    Total Assets Annual Cr 1,1531,140
    IndicatorMar 2024Mar 2023
    Book Value Per Share Annual Rs 9490
    ROE Annual % 59
    ROCE Annual % 1113
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 2324
    IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Oper Rev Qtr Cr 184198201212160185
    Operating Expenses Qtr Cr 149170157158135179
    Operating Profit Qtr Cr 34284454246
    Depreciation Qtr Cr 777665
    Interest Qtr Cr 222115
    Tax Qtr Cr 8111167-4
    Net Profit Qtr Cr 21-92842153
    IndicatorMar 2024Mar 2023
    Total Revenue Annual Cr 799769
    Operating Expenses Annual Cr 620634
    Operating Profit Annual in Cr 151117
    Depreciation Cr 2619
    Interest Annual Cr 710
    Tax Annual Cr 3529
    Net Profit Annual Cr 7571
    IndicatorMar 2024Mar 2023
    Cash from Operating Activity Annual Cr 15234
    Cash from Investing Activity Annual Cr -133-8
    Cash from Financing Annual Activity Cr -21-25
    Net Cash Flow Annual Cr -12
    IndicatorMar 2024Mar 2023
    Total ShareHolders Funds Annual Cr 967884
    Fixed Assets Annual Cr 370374
    Total Non Current Assets Annual Cr 402459
    Total Current Assets Annual Cr 812697
    Total Assets Annual Cr 1,2141,157
    IndicatorMar 2024Mar 2023
    Book Value Per Share Annual Rs 9688
    ROE Annual % 88
    ROCE Annual % 1512
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 2318
    Invest in Bliss GVS Pharma

    Bliss GVS Pharma Technicals

    EMA & SMA

    Current Price
    ₹131.38
    -2.77 (-2.06%)
    pointer
    • Bullish Moving Average
    • ___
    • 16
    • Bearish Moving Average
    • ___
    • 0
    • 20 Day
    • ₹127.22
    • 50 Day
    • ₹121.44
    • 100 Day
    • ₹117.62
    • 200 Day
    • ₹113.59
    • 20 Day
    • ₹128.50
    • 50 Day
    • ₹120.15
    • 100 Day
    • ₹114.09
    • 200 Day
    • ₹118.03

    Bliss GVS Pharma Resistance and Support

    PIVOT
    ₹132.29
    Resistance
    First Resistance 133.83
    Second Resistance 136.28
    Third Resistance 137.82
    RSI 58.89
    MFI 66.00
    MACD Single Line 3.44
    MACD 3.54
    Support
    First Support 129.84
    Second Support 128.30
    Third Supoort 125.85

    Bliss GVS Pharma Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 574,949 30,133,077 52.41
    Week 1,489,978 54,190,507 36.37
    1 Month 1,472,220 58,049,627 39.43
    6 Month 736,114 32,182,913 43.72

    Bliss GVS Pharma Result Highlights

    Bliss GVS Pharma Synopsis

    NSE-Medical-Generic Drugs

    Bliss Gvs Pharma is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 605.46 Cr. and Equity Capital is Rs. 10.47 Cr. for the Year ended 31/03/2024. Bliss GVS Pharma Ltd. is a Public Limited Listed company incorporated on 11/12/1984 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24230MH1984PLC034771 and registration number is 034771.
    Market Cap 1,411
    Sales 645
    Shares in Float 6.83
    No of funds 27
    Yield 0.37
    Book Value 1.42
    U/D Vol ratio 1.9
    LTDebt / Equity 4
    Alpha 0.06
    Beta 1.14

    Bliss GVS Pharma Shareholding Pattern

    Owner NameJun-24Mar-24Dec-23Sep-23
    Promoters 34.9%34.97%34.97%35.06%
    Mutual Funds
    Insurance Companies 6.58%6.59%6.59%6.61%
    Foreign Portfolio Investors 13.24%14.74%15.35%16.31%
    Individual Investors 32.84%31.71%30.78%29.17%
    Others 12.44%11.99%12.31%12.85%

    Bliss GVS Pharma Management

    Name Designation
    Mr. S R Vaidya Chairman & Ind.Director
    Mr. Gagan Harsh Sharma Managing Director
    Dr. Vibha Gagan Sharma Whole Time Director
    Mrs. Shruti Vishal Rao Whole Time Director
    Mr. Santosh L Parab Independent Director
    Ms. Shilpa Bhatia Independent Woman Director

    Bliss GVS Pharma Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Bliss GVS Pharma Corporate Action

    Date Purpose Remarks
    2024-07-24 Quarterly Results
    2024-05-02 Audited Results & Final Dividend
    2024-01-23 Quarterly Results
    2023-11-01 Quarterly Results
    2023-08-01 Quarterly Results

    Bliss GVS Pharma MF Shareholding

    Name Amount(cr)

    Bliss GVS Pharma FAQs

    What is Share Price of Bliss GVS Pharma ?

    Bliss GVS Pharma share price is ₹131 As on 18 September, 2024 | 02:28

    What is the Market Cap of Bliss GVS Pharma ?

    The Market Cap of Bliss GVS Pharma is ₹1381.4 Cr As on 18 September, 2024 | 02:28

    What is the P/E ratio of Bliss GVS Pharma ?

    The P/E ratio of Bliss GVS Pharma is 17 As on 18 September, 2024 | 02:28

    What is the PB ratio of Bliss GVS Pharma ?

    The PB ratio of Bliss GVS Pharma is 1.4 As on 18 September, 2024 | 02:28

    Q2FY23
    Open Free Demat Account

    Be a part of 5paisa community - The first listed discount broker of India.

    +91
     
    footer_form

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI-registered Mutual Fund Distributor | AMFI REGN No.: ARN-104096 | Date of initial Registration: 30/07/2015 | Current validity of ARN : 29/07/2024 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of Rs. 10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of Rs.10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support Desk Helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

    Email: support@5paisa.com

    Support Desk Helpline: 8976689766

    ©2024, 5Paisa Capital Ltd. All Rights Reserved. We are ISO 27001:2013 Certified.